/DTIL
DTIL Stock - Precision BioSciences, Inc.
Healthcare|BiotechnologyNASDAQ
$4.49-0.66%
$0.03 (-0.66%) • Dec 19
66
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.23
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.76
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+245.2%upside
Target: $15.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DTIL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.45 – $4.53
TARGET (TP)$15.50
STOP LOSS$4.13
RISK/REWARD1:30.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.11
52W High$8.82
52W Low$3.61
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $68.70M | $48.73M | $25.10M | $115.53M | $24.29M |
| Gross Profit | $68.70M | $48.73M | $25.10M | $115.53M | $24.29M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-26,162,000 | $-43,736,000 | $-62,308,000 | $-39,376,000 | $-109,828,000 |
| Net Income | $7.17M | $-61,319,000 | $-111,637,000 | $-30,602,000 | $-109,006,000 |
| Net Margin | 10.4% | -125.8% | -444.8% | -26.5% | -448.9% |
| EPS | $1.05 | $-15.96 | $-38.10 | $-15.60 | $-62.85 |
Company Overview
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$20
Average Target
↑ 345.4% Upside
Now
$7
Low
$20
Average
$34
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| January 10th 2025 | BMO Capital Markets | Upgrade | Outperform | $34 |
| April 30th 2024 | Guggenheim | Initiation | Buy | $19 |
| June 17th 2022 | BMO Capital Markets | Initiation | Outperform | $7 |
| June 9th 2022 | William Blair | Downgrade | Market Perform | - |
Earnings History & Surprises
DTILBeat Rate
53%
Last 19 quarters
Avg Surprise
-140.1%
EPS vs Estimate
Beats / Misses
10/9
Last 12 quarters
Latest EPS
$-1.84
Q4 2025
EPS Surprise History
Q1 24
-211.7%
$-3.35vs$3.00
Q2 24
+22.2%
$-0.35vs$-0.45
Q3 24
+549.4%
$3.46vs$-0.77
Q4 24
-258.2%
$-2.83vs$-0.79
Q1 25
-53.1%
$-3.20vs$-2.09
Q2 25
-414.0%
$-2.21vs$-0.43
Q3 25
-2266.7%
$-2.13vs$-0.09
Q4 25
-493.5%
$-1.84vs$-0.31
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | $-0.21 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.31 | $-1.84 | -493.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.09 | $-2.13 | -2266.7% | ✗ MISS |
Q2 2025 | May 15, 2025 | $-0.43 | $-2.21 | -414.0% | ✗ MISS |
Q1 2025 | Mar 26, 2025 | $-2.09 | $-3.20 | -53.1% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.79 | $-2.83 | -258.2% | ✗ MISS |
Q3 2024 | Aug 1, 2024 | $-0.77 | $3.46 | +549.4% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.45 | $-0.35 | +22.2% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $3.00 | $-3.35 | -211.7% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-5.71 | $-3.00 | +47.5% | ✓ BEAT |
Q3 2023 | Aug 4, 2023 | $-6.91 | $-3.00 | +56.6% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-6.61 | $-6.91 | -4.5% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-7.21 | $-7.81 | -8.3% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-10.51 | $-6.61 | +37.1% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-12.91 | $-13.21 | -2.3% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-17.42 | $-13.81 | +20.7% | ✓ BEAT |
Q1 2022 | Mar 15, 2022 | $-14.41 | $-11.41 | +20.8% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-18.02 | $-5.71 | +68.3% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-11.41 | $10.81 | +194.7% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-14.71 | $-9.91 | +32.6% | ✓ BEAT |
Latest News
Precision BioSciences Announces ~$75M Underwritten Offering Of 10.815M Shares And Accompanying Warrants To Purchase Up To 5,407,500 Shares Of Common Stock At A Combined Price Of $6.14
➖ NeutralBenzinga•Nov 10, 2025, 11:25 PM
Trading Halt: Halt status updated at 5:50:00 PM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Nov 10, 2025, 10:50 PM
Precision BioSciences' First-in-Class Gene Editing Therapy PBGENE-HBV Shows Dose-Dependent Antiviral Response And Evidence Of Viral DNA Editing In Phase 1 ELIMINATE-B Study, Offering Potential Path Toward Chronic Hepatitis B Cure; To Host Conference Call Tomorrow, November 11th At 8:00 am ET
📈 PositiveBenzinga•Nov 10, 2025, 10:25 PM
Trading Halt: Halted at 4:55:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Nov 10, 2025, 09:55 PM
Precision BioSciences shares are trading lower after the company reported worse-than-expected Q3 financial results.
📉 NegativeBenzinga•Nov 3, 2025, 04:51 PM
Precision BioSciences Q3 EPS $(1.84) Misses $(1.34) Estimate, Sales $13.000K Miss $5.400M Estimate
📉 NegativeBenzinga•Nov 3, 2025, 12:01 PM
Precision BioSciences To Present New PBGENE-HBV Phase 1 Data Showing Safety And Antiviral Activity At AASLD Liver Meeting 2025 On Nov 10 In Washington, DC
📈 PositiveBenzinga•Oct 14, 2025, 11:08 AM
Precision Biosciences Announced The Publication Demonstrating A Wide Variety Of Gene Edits Using ARCUS Nucleases To Stimulate A Homology Dependent Repair Mechanism
📈 PositiveBenzinga•Oct 9, 2025, 11:20 AM
Precision BioSciences Opens First U.S. ELIMINATE-B Site At Massachusetts General Hospital, Actively Recruiting Chronic Hepatitis B Patients
📈 PositiveBenzinga•Oct 7, 2025, 11:16 AM
iECURE To Present OTC-HOPE Clinical Trial Data Of ECUR-506 In Ornithine Transcarbamylase Deficiency
➖ NeutralBenzinga•Oct 2, 2025, 12:08 PM
Precision BioSciences Announces Late-Breaking Poster Presentation At WMS 2025; To Highlight Latest Long-Term Preclinical Efficacy And Durability Data Supporting PBGENE-DMD For Duchenne Muscular Dystrophy Treatment
📈 PositiveBenzinga•Sep 30, 2025, 11:06 AM
Precision BioSciences Presents Clinical Data From Phase 1 ELIMINATE-B Trial Of PBGENE-HBV In Patients With Chronic Hepatitis B At ICE-HBV
➖ NeutralBenzinga•Sep 12, 2025, 11:02 AM
Precision Biosciences To Be Issued Us Patent For PBGENE-HBVARCUS Nuclease Utilized In The Company's Lead In Vivo Gene Editing Program, The Us Patent Will Have An Expiration Date In March 2042
📈 PositiveBenzinga•Sep 8, 2025, 11:10 AM
iECURE Announces It Will Present Additional Data From Its Ongoing OTC-Hope Clinical Trial Of ECUR-506 For Neonatal Onset Ornithine Transcarbamylase Deficiency At Two Upcoming Conferences In Kyoto, Japan
📈 PositiveBenzinga•Aug 25, 2025, 12:09 PM
Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%
📈 PositiveSeeking Alpha•Jun 25, 2025, 01:29 PM
Frequently Asked Questions about DTIL
What is DTIL's current stock price?
Precision BioSciences, Inc. (DTIL) is currently trading at $4.49 per share. The stock has moved -0.66% today.
What is the analyst price target for DTIL?
The average analyst price target for DTIL is $15.50, based on 1 analyst.
What sector is Precision BioSciences, Inc. in?
Precision BioSciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DTIL's market cap?
Precision BioSciences, Inc. has a market capitalization of $0.06 billion, making it a small-cap company.
Does DTIL pay dividends?
No, Precision BioSciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ALXO
ALX Oncology Holdings Inc.
$1.45
Mkt Cap: $0.1B
ARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
ATYR
aTyr Pharma, Inc.
$0.75
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
QNCX
Quince Therapeutics, Inc.
$3.57
Mkt Cap: $0.2B
RPTX
Repare Therapeutics Inc.
$2.14
Mkt Cap: $0.1B
STRO
Sutro Biopharma, Inc.
$9.98
Mkt Cap: $0.1B
Explore stocks similar to DTIL for comparison